Scientist II/Senior Scientist I, Complex Human Systems

Are you ready to build the human heart and kidney models that decide which of Gordian’s novel targets become medicines — from primary cells and iPSC-derived cells to organoids and engineered heart tissue, all from the bench?

Gordian is the leader in applying in vivo screening for target discovery. Our screens are producing novel targets faster than traditional discovery can, but a target found in an animal only becomes a medicine if the biology holds in human cells and tissue. As our Scientist II / Senior Scientist I, Complex Human Systems, you will build the human models of HFpEF and CKD/DKD that test our targets, deliver a clear human-relevance call on each, and give our small molecule programs disease-relevant human assays to design against.

Journey + Destination:

Gordian Biotechnology is a therapeutics company designed as a machine that systematically reveals the right way to cure age-related diseases: a machine for creating time.

To do that, we built Mosaic Screening, which makes causal validation both grounded in human pathophysiology and radically more scalable in living diseased tissue. It lets us measure the causal effects of hundreds of perturbations directly in vivo, which reveals therapeutic maxima across vast target spaces (more details on our website and in our preprint). The machine is already producing wins: across six disease areas, we have mapped nearly as many targets as the field reported in 20 years, advanced a novel osteoarthritis candidate into IND-enabling studies, and started an obesity drug-discovery collaboration with Pfizer.

But there are still many diseases left to cure, and expanding the machine to tackle them starts with its most important resource: its people and culture. We work as a team, using clear goals, open communication, and direct feedback to make autonomous decisions with the bigger picture in mind. We aim for extraordinary outcomes, continually improving how we work and acting on what will create the most progress, even in unknown territory. We have deliberately designed an environment to sustain that standard: few standing meetings, hands-on experimentation and pre-mortems, weekly team lunches, and unlimited vacation that people are encouraged to use. You can dive deeper into our culture here.

This way of working has been crucial to Gordian’s success. In this role, you will help prove that the targets the machine produces work in human biology.


The Role:

Working within our Ex Vivo and Assay (EVA) team, and closely with our in vivo, in vitro pharmacology, medicinal chemistry, single-cell and computational biology teams and disease leads, your mission is to make four things work across our heart failure (HFpEF) and kidney (CKD/DKD) programs:

  1. Complex human models. You will establish human primary cell cultures, iPSC-derived cardiomyocytes, 3D organoids (including kidney PTEC organoids) and engineered heart tissue, and bring them to the point where they reproduce disease biology: diastolic dysfunction, cardiomyocyte stiffening, inflammation, tubular injury and fibrosis.
  2. Target validation in human systems. You will take hits from our in vivo screens and confirmation studies into these models, perturb them with siRNA/ASO, AAV, CRISPR or tool compounds against readouts and go/no-go criteria set up front, and deliver a written call on each: does modulating the target move a disease readout in human cells, in which cell type, and by how much.
  3. Human assays for small molecule programs. Through working with our in vitro pharmacology and chemistry teams, you will develop target engagement, mechanism of action and phenotypic efficacy assays in disease-relevant human systems, benchmark against standard-of-care drugs, and flag cytotoxicity or model artifacts before they reach a key decision.
  4. Translational quality. You will identify the critical-path experiments that de-risk each program, benchmark our human data against published and competitor data, and keep designs cost-effective, reproducible and anchored to gold-standard models.

You will work hands-on with human tissue as well as cells: processing donor heart and kidney tissue under BSL-2 and bloodborne pathogen procedures, supporting precision-cut heart and kidney slice culture with our ex vivo team, and helping manage tissue suppliers, donor metadata and consent documentation. You will read out biology with confocal and high-content imaging, histology and immunostaining, and with our single-cell and computational biology teams, use single-cell, single-nucleus and spatial transcriptomics to map model cell states against human heart and kidney atlases. You will record your work in Clio, write SOPs others can follow, and train Research Associates to run established models without error. Senior Scientist I hires will own one human program end to end with minimal input from the EVA team lead and disease lead, own human sample procurement, and mentor junior scientists.

Knowing what a model can and cannot tell us is the heart of this role. Getting an organoid to grow is not enough. You will know which cell states your model contains, how immature iPSC-derived cells differ from adult human tissue, and how a phenotype can be an artifact of culture stress, batch or donor. When a model drifts or two donors disagree, you find the root cause by isolating variables, not by re-running until it works. Every claim of human relevance that leaves your bench is backed by single-cell or imaging data comparing the model with human tissue.

One thing to be clear about: this is a hands-on role. Roughly 70% of your time is building, running and troubleshooting human systems in our lab. The rest is experimental design, analysis, SOP writing, training and communication. We are not looking for someone who runs a published protocol as written and reports what came out, or who spends a year perfecting a model that never answers a program question. Every model exists to make a target or compound decision.

In your first month, learn Gordian’s platform well enough to explain it unaided to an external partner; get up to speed on the target validation packages and status of our HFpEF and CKD/DKD programs; become proficient in our established ex vivo cultures, including human myocardial and precision-cut kidney slices; audit our existing human models and gaps; and write a pre-mortemed plan for your first human system.

By two months, your first human system will be running in our lab, for example iPSC-cardiomyocyte engineered heart tissue or a primary cardiac co-culture, with functional readouts such as contraction, relaxation and calcium transients, and positive and negative controls. Target delivery will be optimized with knockdown or expression confirmed, and the plan for a second (CKD/DKD) system will be drafted.

By three months, your first system will be validated, with the disease phenotype reproduced and a benchmark drug or target effect confirmed, and development of your second model will have launched.

By six months, you will have completed your first round of target validation in an HFpEF or CKD/DKD system, each target with a written human-relevance call, at least one human assay will be supporting an active small molecule program

By twelve months, you will have completed a second round of target validation, your human model data will have informed at least one target nomination or go/no-go decision, and you will have brought a new capability online, such as vascularized organoids or spatial transcriptomics for human disease models. Over time, you will become the person who tells us which human model can answer the question for each new indication, and how fast we can stand it up.

And You:

You have a track record of success in high-agency work, consistently creating momentum rather than waiting for direction.

You want to do your best work alongside exceptional teammates and are energized by environments where people push each other to think more clearly, work at a higher standard, and grow into better versions of themselves.

You truly want to play a key role in an early-stage startup turning novel targets into medicines and curing diseases of aging: a fast-paced environment full of both uncertainty and new challenges, demanding relentless resourcefulness.

You build human models, not just run them. You maintain iPSC lines with pluripotency and karyotype QC and differentiate them reproducibly (purity by flow) into cardiomyocytes. You have personally built a kidney or cardiac organoid or multicellular co-culture and improved its fidelity, maturation or reproducibility, and you can walk through a failed batch and exactly what you changed to fix it.

You bring the training. You have a Ph.D. in cell biology, physiology, pharmacology, bioengineering or a related field, plus postdoctoral training in cardiovascular, renal or stem cell biology. For Scientist II, that means 2-5 years post-Ph.D.; for Senior Scientist I, 4-8 years post-Ph.D., ideally including industry drug discovery and experience mentoring junior scientists or Research Associates.

You understand cardio-renal disease. You have a background in heart failure (ideally HFpEF) and/or CKD/DKD, and you can explain what a human model must reproduce to be useful: diastolic stiffness, microvascular inflammation, metabolic stress, tubular injury and fibrosis.

You know the limits of your models. You understand how immature iPSC-derived cells differ from adult tissue and have used maturation strategies to address it. You recognize when a phenotype comes from culture stress, batch or donor, design experiments with the right replicates (donors, differentiations, technical) and statistics, and find root causes by isolating variables.

You communicate so that decisions follow. You can explain what a model shows, and what it does not, to biologists, chemists and leadership, and you bring a clear recommendation rather than a data dump.

You want to be in the lab. Building and troubleshooting models will be most of your week, and you are comfortable with the long-term culture schedule this requires, including light weekend maintenance.

Additional valuable skills if you have them

  • Isolation and culture of primary cells from human heart or kidney tissue, including handling donor variability, purity and dedifferentiation.
  • Industry drug discovery or development experience.
  • Inducing disease phenotypes in human systems and using them to validate targets or compounds with pre-set criteria.
  • Human myocardial slices, human kidney slices, or engineered heart tissue with force, relaxation and calcium readouts.
  • Vibratome and cryosectioning proficiency.
  • Single-cell or single-nucleus RNA-seq, including hands-on analysis.
  • Confocal and high-content imaging with quantitative image analysis (e.g., CellProfiler, Imaris, Harmony, ImageJ or Python).
  • Target engagement, mechanism of action or phenotypic assay development for small molecule programs.
  • CRISPR KO/CRISPRi or isogenic iPSC line generation.
  • Target delivery with AAV, lentivirus, LNP or siRNA/ASO.
  • Functional cardiac readouts such as calcium imaging, contractility (e.g., IonOptix), MEA or optical mapping.
  • Microphysiological systems: organ-on-chip, perfused or vascularized organoids.
  • Human tissue governance: IRB and consent, donor metadata and tissue supplier management.
  • A peer-reviewed first-author publication record in human in vitro models or cardio-renal biology.

The Details:

Gordian aims to provide everything you need to thrive. Beyond our community and science, you’ll have enough equity to be a true stakeholder in the company, competitive salary, full health/dental/vision/life insurance, 401k with match, onsite lunch paid for 3 days a week, whatever vacation you need to be at your peak, remote work flexibility, and access to world-class mentors and advisors to support your professional growth. Our building is in the heart of the biotech capital of South San Francisco.

L'échelle de rémunération pour ce poste est :

125 000–190 000 USD par an (South San Francisco)

Ex Vivo

South San Francisco, CA

Partager sur :